Skip to content

Yuva Sath: A Peer-led Behavioral Intervention to Support Substance Use Treatment and HIV Prevention Among Young People Who Inject Drugs in India

Yuva Sath: A Peer-led Behavioral Intervention to Support Substance Use Treatment and HIV Prevention Among Young People Who Inject Drugs in India

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06510192
Enrollment
60
Registered
2024-07-19
Start date
2027-01-31
Completion date
2028-12-31
Last updated
2025-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hiv, Substance Use Disorders

Keywords

Youth, India, People who inject drugs

Brief summary

The goal of this pilot randomized controlled trial is to learn if Yuva Sath, a youth-tailored peer-led behavioral intervention, can support substance use treatment engagement and HIV prevention among young people who inject drugs in India. The main questions it aims to answer are: * Is Yuva Sath feasible and is it acceptable to young people who inject drugs in India ? * Can Yuva Sath improve engagement in substance use treatment, increase use of HIV prevention services and decrease substance use and risk behaviors among young people who inject drugs in India ? Researchers will compare participants who receive the Yuva Sath behavioral intervention to participants who do not to see if the behavioral intervention improves substance use treatment engagement and HIV prevention. Participants will: * Receive a total of 6 one-on-one sessions, and weekly phone text check-ins from peer counselors over a course of 6 months. * Complete monthly random urine drug screens * Complete in-person study questionnaires every 3 months * Report substance use and risk behaviors weekly to peer counselors through a brief phone text message survey

Interventions

BEHAVIORALYuva Sath

The Yuva Sath Intervention comprises 6 one-on-one sessions with peer counselors who will use an intervention manual. The intervention also includes weekly phone text check-ins by peer counselors

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 29 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-29 years; * Receiving medications for opioid use disorder (MOUD) for at least 3 months and receipt frequency \< 2 times a week

Exclusion criteria

* Receiving medications for opioid use disorder (MOUD) for less than 3 months and receipt frequency \>= 2 times a week * Requiring urgent medical attention * Inability to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of the Yuva Sath Intervention: Peer counselor fidelity6 months.Feasibility of the Yuva Sath intervention as measured by peer counselor fidelity to the intervention protocol will be determined by independent observer fidelity checklists. The checklist will score content delivery on a 3-point ordinal scale (1=no key content covered to 3=all key content covered), and peer-navigator actions (i.e., identification of barriers; generation of solutions) on a 5-point Likert scale (1=not at all to 5=very much). The intervention will be deemed to be feasible if 80% of the sessions addressed key Life-Steps module content and employed flexible problem-solving
Feasibility of the Yuva Sath Intervention: Attendance in the first four sessions6 monthsFeasibility of the Yuva Sath intervention as measured by attendance in the first four sessions will be calculated as a proportion: participants who completed the first four sessions of the total 6 sessions of the intervention/ All participants in the intervention arm. The intervention will be deemed to be feasible if at least 75% of participants completed the first four sessions
Feasibility of the Yuva Sath Intervention: Completion of the 3 month assessment3 monthsFeasibility of the Yuva Sath intervention as measured by completion of the 3 month session will be calculated as a proportion: participants who completed the 3 month assessment / All participants in the intervention arm. The intervention will be deemed feasible if at least 60% of participants completed the 3-month assessment
Acceptability of the Yuva Sath Intervention6 monthsAcceptability of the intervention as measured by the overall satisfaction of participants rated on a 5-point Likert scale (1=not at all to 5=very much). The intervention will be deemed acceptable if at least 75% of the participants rate \>=4 on overall satisfaction

Secondary

MeasureTime frameDescription
Substance use: Self report at 3-month assessment3 monthsSubstance use as measured by self report will be compared between the intervention and control arms. We will calculate the proportion of participants (%) in the intervention and control arms who report continued substance use by at the 3-month assessment
Substance use: Self report at 6-month assessment6 monthsSubstance use as measured by self report will be compared between the intervention and control arms. We will calculate the proportion (%) of participants in the intervention and control arms who report continued substance use by at the 6-month assessment
Substance use: monthly random point-of-care urinalysis6 monthsSubstance use as measured by monthly point-of-care urinalysis will be compared between the intervention and control arms. We will calculate the proportion (%) of participants in the intervention and control arms who had at least one positive point-of-care test for opioids (excluding buprenorphine) in each arm
Substance use treatment engagement: the number of MOUD visits each month6 monthsSubstance use treatment engagement as measured by the average number of MOUD visits each month over a 6 month period will be compared between the intervention and control arms.
Needle sharing: self report at 6-month assessment6 monthsNeedle sharing as measured by self report will be compared between the intervention and control arms. We will calculate the proportion of participants (%) in the intervention and control arms who report needle sharing at the 6-month assessment
Condomless sex: self report at 3-month assessment.3 monthsCondomless sex as measured by self report will be compared between the intervention and control arms. We will calculate the proportion of participants (%) in the intervention and control arms who report condomless sex at the 3-month assessment
Condomless sex: self report at 6-month assessment.6 monthsCondomless sex as measured by self report will be compared between the intervention and control arms. We will calculate the proportion of participants (%) in the intervention and control arms who report condomless sex at the 6-month assessment
Needle sharing: Self report at 3-month assessment3 monthsNeedle sharing as measured by self report will be compared between the intervention and control arms. We will calculate the proportion of participants (%) in the intervention and control arms who report needle sharing at the 3-month assessment
Substance use treatment engagement: the number of weeks of MOUD receipt at >2 times a week6 monthsSubstance use treatment engagement as measured by the the number of weeks of MOUD receipt at \>2 times a week will be compared between the intervention and control arms. We will calculate the proportion of participants (%) in each arm who on average received MOUD at a frequency of \> 2 times a week.
Substance use treatment engagement: retention in MOUD at 6 months6 monthsSubstance use treatment engagement as measured by retention in MOUD at 6 months will be compared between the intervention and control arms. We will calculate the proportion (%) of participants in each arm who were retained in MOUD at 6 months
HIV testing receipt6 monthsReceipt of regular HIV testing every 6 months will be compared between the intervention and control arms. We will calculate the proportion (%) of participants in each arm who received regular HIV testing

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026